BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is expected to report second quarter earnings results, after market close, on Tuesday 4th August 2020.
Analysts polled by Thomson Reuters anticipate second quarter loss of $ 0.11 per share.
Looking ahead, the full year income are expected at $ 0.27 per share on the revenues of $ 1899.70 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 1,850.00 million ~ $ 1,950.00 million
Click Here For More Historical Outlooks Of BioMarin Pharmaceutical Inc.
Previous Quarter Performance
BioMarin Pharmaceutical Inc. revealed income for the first quarter of $ 0.44 per share, from the revenue of $ 502.07 million. The quarterly earnings increased 87.10 percent while revenues compared with the same quarter last year.
According to street consensus, BMRN was expected to report 1Q20 income of $ 0.05 per share from revenue of $ 468.77 million. The bottom line results beat street analysts by $ 0 or , at the same time, top line results outshined analysts by $ 33.30 million or 7.10 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of BioMarin Pharmaceutical Inc.
Stock Performance
According to the previous trading day, closing price of BMRN was $ 122.04, representing a 94.08 % increase from the 52 week low of $ 62.88 and a 7.51 % decrease over the 52 week high of $ 131.95.
The company has a market capital of $ 22.07 billion and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”BMRN” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Recent Analyst recommendations
- On 8th July 2020, downgraded by Morgan Stanley to Equal-Weight from Overweight rating.
- On 18th June 2020, maintained by SunTrust Robinson Humphrey at Buy rating, with $ 143.00 target price.
- On 18th June 2020, maintained by Oppenheimer at Perform rating, with $ 95.00 target price.
- On 10th June 2020, maintained by Bank of America at Buy rating, with $ 130.00 target price.
Conference Call
BioMarin Pharmaceutical Inc. will be hosting a conference call at 4:30 PM eastern time on 4th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.biomarin.com
BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The companys commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder; and Firdapse for lambert eaton myasthenic syndrome.
